Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

CEO of ICPAO Yandex Artem Savinovsky appointed

4/11/24 YNDX

Gazprom Neft migrated to Astra Linux for 85% employees

4/11/24 ASTR

Board of Directors of Rosbank recommended dividends

4/10/24 ROSB

Southern Kuzbass reported for 2023 by IFRS

4/10/24 UKUZ

SberUnity launched syndicated transactions

4/10/24 SBER

Board of Directors of NLMK recommended dividends

4/10/24 NLMK

SberUnity launched syndicated transactions

4/10/24 OTCI

Korshunovsky GOK reported for 2023 by IFRS

4/10/24 KOGK

Shareholders of Positive Technologies Group approved dividends

4/10/24 POSI

Lukoil launches damaged unit at Volgograd Refinery

4/10/24 LKOH